Opinion|Videos|January 17, 2025

Anitocabtagene Autoleucel in Focus: Insights From the iMMagine-1 Trial at ASH 2024

Saad Z. Usmani, MD, MBA, FACP, discusses how the iMMagine-1 trial, presented at ASH 2024, evaluated the novel chimeric antigen receptor (CAR) T-cell therapy anitocabtagene autoleucel, detailing its study objectives, design, and methodology as well as the promising results that highlight its potential to advance treatment options for multiple myeloma.

Video content above is prompted by the following:

  • Discuss the novel CAR T-cell therapy anitocabtagene autoleucel, as studied in the iMMagine-1 trial and presented at ASH 2024.
  • What was the objective of this study?
  • How was this study designed/what methodology was used?
  • What results were presented?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo